S
Sana Biotechnology, Inc. (SANA)
NMS – Real vaqt narxi. Valyuta: USD
3.26
-0.30 (-8.43%)
Yopilishda: May 12, 2026, 4:00 PM EDT
3.34
+0.08 (2.45%)
Bozor oldidan: May 13, 2026, 4:01 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
3.26
-0.30 (-8.43%)
Yopilishda: May 12, 2026, 4:00 PM EDT
3.34
+0.08 (2.45%)
Bozor oldidan: May 13, 2026, 4:01 AM EDT
Sana Biotechnology, Inc., biotexnologiya kompaniyasi, Qo'shma Shtatlarda muolajalar sifatida muhandislik qilingan hujayralardan foydalanishga qaratilgan. U turli terapevtik sohalar uchun ex vivo va in vivo hujayra muhandisligi platformalarini ishlab chiqadi, shu jumladan 1-toifa diabet, B-hujayrali autoimmün kasalliklar va onkologiya. Kompaniyaning mahsulot quvuri UP421ni o'z ichiga oladi, bu HIP tomonidan modifikatsiyalangan allogenik birlamchi orolcha hujayra mahsuloti bo'lib, u 1-toifa diabetni davolash uchun 1-fazali klinik sinovda; SC451, HIP tomonidan modifikatsiyalangan, ildiz hujayralaridan olingan oshqozon osti bezi orolcha hujayra terapiyasi, u 1-toifa diabetni davolash uchun preklinik sinovda; SG293 va SG299, B-hujayrali gematologik malignliklar va B-hujayrali autoimmün kasalliklarni davolash uchun CD8-ni maqsad qilgan fusosome. Kompaniya Beam Therapeutics Inc. bilan Beamning patentlangan CRISPR Cas12b nukleaz tahrir texnologiyasidan foydalanish bo'yicha opsion va litsenziya shartnomasiga ega; va gipoymun-modifikatsiyalangan hujayra terapiyasi mahsulotlarini tadqiq qilish, ishlab chiqish va tijoratlashtirish uchun; va gipoymun-modifikatsiyalangan hujayralarni ishlab chiqish uchun ma'lum bir intellektual mulkka kirish uchun Garvard kolleji bilan litsenziya shartnomasiga ega. Kompaniya Mayo Clinic bilan 1-toifa diabet uchun gipoymun-modifikatsiyalangan oshqozon osti bezi orolcha hujayra terapiyasi bo'lgan SC451ni ishlab chiqish bo'yicha strategik hamkorlikni yo'lga qo'ygan. Kompaniya ilgari FD Therapeutics, Inc. nomi bilan tanilgan va 2018-yil sentyabr oyida Sana Biotechnology, Inc. nomini olgan. Sana Biotechnology, Inc. 2018-yilda tashkil etilgan va shtab-kvartirasi Sietl, Vashingtonda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Dhavalkumar D. Patel M.D., Ph.D. | Executive VP & Chief Scientific Officer |
| Dr. Gary Meininger M.D. | Chief Medical Officer |
| Dr. Steven D. Harr M.D. | President, CEO & Director |
| Dr. Yuko Soneoka J.D., Ph.D. | Head of Intellectual Property |
| Mr. Aaron M. Grossman | Executive VP, Chief Legal Officer & Corporate Secretary |
| Mr. Brian D. Piper M.B.A. | Executive VP & CFO |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-11 | 8-K | sana-20260511.htm |
| 2026-04-24 | DEFA14A | d48188ddefa14a.htm |
| 2026-04-24 | DEF 14A | d42230ddef14a.htm |
| 2026-03-03 | S-3ASR | d113291ds3asr.htm |
| 2026-02-17 | 8-K | sana-20260217.htm |
| 2026-01-14 | 8-K | sana-20260114.htm |
| 2025-11-06 | 10-Q | sana-20250930.htm |
| 2025-09-05 | 8-K | sana-20250904.htm |
| 2025-08-29 | 8-K | sana-20250828.htm |
| 2025-08-13 | CORRESP | filename1.htm |
| Mr. John Gerecitano M.D., Ph.D. | Head of Oncology Research & Development |
| Mr. Snehal Patel | Senior VP & Chief Technical Officer |
| Ms. Debra Wisdom | VP & Head of People |
| Ms. Susan Wyrick | Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting |